Vistagen Therapeutics has received a Fast Track designation from the U.S. FDA for its Ph94B nasal spray for the on-demand treatment of social anxiety disorder (SAD), the second most commonly diagnosed anxiety disorder, which affects 20 million Americans. Since SAD patients lack effective treatments and have considerable unmet medical need, the FDA has granted it this special status that should accelerate the clinical trials process to get the treatment into patients hands as soon as possible. Although fast-tracked clinical trials bring their own set of logistical challenges, Yourway is well positioned to support clients' clinical trials using these approval pathways.